Leading endpoint data capture platform combining eCOA,cardiac safety,medical imaging,precision motion,and respiratory endpoints. Acquired by Thermo Fisher for $8.9B. Supported 19,000+ trials and 870+ regulatory approvals.
Vendor description
Enterprise multi-modal endpoint data capture platform
Complex multi-endpoint trials,Cardiac safety,Medical imaging,eCOA + imaging combined
- Only platform combining eCOA,cardiac safety,imaging,motion,respiratory
- 19,000+ trials supported
- 870+ regulatory approvals
- Thermo Fisher ecosystem integration
- Premium pricing
- Complex implementation
- Tied to Thermo Fisher ecosystem
Approved customer reviews
Write a reviewNo reviews yet
Be the first customer to share verified experience with this vendor.
Pricing
$
Key facts
| HQ country | United States |
|---|---|
| Geography | Global |
| Service model | Full-service + Technology |
| Study phases | Phase I, Phase II, Phase III, Phase IV |
| Trial scale | Medium,Large,Global |
| Therapeutic areas | Oncology, Cardiovascular, Respiratory, Neurology, Rare diseases, Ophthalmology |
Related vendors
Editorial ranking
See how Clario (Thermo Fisher) compares - best Medical imaging vendors for clinical trials.


